Literature DB >> 11316511

Antiretroviral therapeutic possibilities for human immunodeficiency virus/acquired immunodeficiency syndrome.

G A Balint1.   

Abstract

In human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) illness, the reverse transcriptase and protease (PRT) enzymes of HIV are currently the targets of antiretroviral (ARV) therapy. Nucleoside analogues were the first group of ARV drugs that exerted antiviral activity in patients. More recently, PRT inhibitors have provided new approaches in the treatment of HIV infection and AIDS. Impressive clinical results have been obtained with combination therapies of three ARV drugs, including one PRT inhibitor. It is worth mentioning also that apart from these two main drug groups, there are many new compounds under development, including a vaccine(s) against HIV.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11316511     DOI: 10.1016/s0163-7258(00)00101-7

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  1 in total

1.  Disposition and oral bioavailability in rats of an antiviral and antitumor amino acid phosphoramidate prodrug of AZT-monophosphate.

Authors:  Heng Song; Rachel Johns; George W Griesgraber; Carston R Wagner; Cheryl L Zimmerman
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.